For instance, combining CTLA‐4 inhibitors with PD‐1/PD‐L1 antibodies can activate the INF‐γ pathway and other pathways, potentially inducing the upregulation of additional immune checkpoints on tumor‐infiltrating lymphocytes, ultimately resulting in treatment failure. The gene discussed is CTLA4; the disease is neoplasm.